Subbarao Padmaja, Milla Carlos, Aurora Paul, Davies Jane C, Davis Stephanie D, Hall Graham L, Heltshe Sonya, Latzin Philipp, Lindblad Anders, Pittman Jessica E, Robinson Paul D, Rosenfeld Margaret, Singer Florian, Starner Tim D, Ratjen Felix, Morgan Wayne
1 Division of Respiratory Medicine, Department of Pediatrics, Physiology, and Experimental Medicine, The Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
2 Lucile Salter Packard Children's Hospital, Stanford University, Palo Alto, California.
Ann Am Thorac Soc. 2015 Jun;12(6):932-9. doi: 10.1513/AnnalsATS.201501-021FR.
The lung clearance index (LCI) is a lung function parameter derived from the multiple-breath washout (MBW) test. Although first developed 60 years ago, the technique was not widely used for many years. Recent technological advances in equipment design have produced gains in popularity for this test among cystic fibrosis (CF) researchers and clinicians, particularly for testing preschool-aged children. LCI has been shown to be feasible and sensitive to early CF lung disease in patients of all ages from infancy to adulthood. A workshop was convened in January 2014 by the North American Cystic Fibrosis Foundation to determine the readiness of the LCI for use in multicenter clinical trials as well as clinical care. The workshop concluded that the MBW text is a valuable potential outcome measure for CF clinical trials in preschool-aged patients and in older patients with FEV1 in the normal range. However, gaps in knowledge about the choice of device, gas, and standardization across systems are key issues precluding its use as a clinical trial end point in infants. Based on the current evidence, there are insufficient data to support the use of LCI or MBW parameters in the routine clinical management of patients with CF.
肺清除指数(LCI)是一种从多次呼吸冲洗(MBW)测试得出的肺功能参数。尽管该技术在60年前就已首次开发,但多年来并未得到广泛应用。设备设计方面的最新技术进步使得这项测试在囊性纤维化(CF)研究人员和临床医生中越来越受欢迎,尤其是在测试学龄前儿童时。LCI已被证明在从婴儿期到成年期的所有年龄段患者中,对于早期CF肺部疾病都是可行且敏感的。2014年1月,北美囊性纤维化基金会召开了一次研讨会,以确定LCI用于多中心临床试验以及临床护理的准备情况。研讨会得出结论,MBW测试对于学龄前患者以及FEV1在正常范围内的老年患者的CF临床试验而言,是一种有价值的潜在结局指标。然而,关于设备选择、气体以及系统间标准化方面的知识空白是阻碍其作为婴儿临床试验终点的关键问题。基于目前的证据,尚无足够数据支持在CF患者的常规临床管理中使用LCI或MBW参数。